Advanced SearchSearch Tips
Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response
Elnemr, Gamal M; El-Rashidy, Ahmed H; Osman, Ahmed H; Issa, Lotfi F; Abbas, Osama A; Al-Zahrani, Abdullah S; El-Seman, Sheriff M; Mohammed, Amrallah A; Hassan, Abdelghani A;
  PDF(new window)
Triple-negative breast cancers constitute about 15% of all cases, but despite their higher response to neoadjuvant chemotherapy, the tumors are very aggressive and associated with a poor prognosis as well as a higher risk of early recurrence. This study was retrospectively performed on 101 patients with stage II and III invasive breast cancer who received 6-8 cycles of neo-adjuvant chemotherapy. Out of the total, 23 were in the triple negative breast cancer subgroup. Nuclear Ki-67 expression in both the large cohort group (n
Triple negative breast cancer;neoadjuvant chemotherapy;Ki-67;pathological response;
 Cited by
The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis, Future Oncology, 2017, 13, 9, 843  crossref(new windwow)
Anders CK, Carey LA (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer, 9, 73-81. crossref(new window)

Andre F, Zielinski C (2012). Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncology, 23, 46-51. crossref(new window)

Aysola K, Desai A, Welch C, et al (2013). Triple negative breast cancer-an overview. Hereditary Genetics: Current Research, 2013.

Berrada N, Delaloge S, Andre F (2010). Treatment of triplenegative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol, 21, 30-5. crossref(new window)

Bidard F-C, Matthieu M-C, Chollet P, et al (2008). p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol, 19, 1261-5. crossref(new window)

Burstein HJ, Harris JR, Morrow M (2008). Malignant tumors of the breast. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott, Williams & Wilkins, 1606-54.

Edge SB, Byrd DR, Compton CC, et al (2010). AJCC cancer staging manual, Springer New York.

Gerdes J, Li L, Schlueter C, et al (1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol, 138, 867.

Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol, 492.

Inwald E, Klinkhammer-Schalke M, Hofstädter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients:results of a large population-based cohort of a cancer registry. Breast Cancer Res Treatment, 139, 539-52. crossref(new window)

Keam B, Im S-A, Lee K-H, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22.

Liedtke C, Mazouni C, Hess KR, et al (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81. crossref(new window)

Liu M, Mo QG, Wei CY, et al (2013). Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis. Oncology letters, 5, 983-91. crossref(new window)

Luporsi E, Andre F, Spyratos F, et al (2012). Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treatment, 132, 895-915. crossref(new window)

Masuda H, Baggerly KA, Wang Y, et al (2013). Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. ASCO Annual Meeting Proc, 1005.

Mayer IA, Abramson VG, Lehmann BD, et al (2014). New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clinical Cancer Res, 20, 782-90. crossref(new window)

Milde-Langosch K, Karn T, Muller V, et al (2013). Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treatment, 137, 57-67. crossref(new window)

Peddi PF, Ellis MJ, Ma C (2011). Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer, 2012.

Rocca A, Viale G, Gelber RD, et al (2008). Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemotherapy Pharmacol, 61, 965-71. crossref(new window)

Silver DP, Richardson AL, Eklund AC, et al (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28, 1145-53. crossref(new window)

Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. crossref(new window)

Von Minckwitz G, Martin M (2012). Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol, 23, 35-9.

Yerushalmi R, Woods R, Ravdin PM, et al (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. crossref(new window)